Oxford Launches First Human Trial of Bundibugyo Ebola Vaccine

The University of Oxford launched the world's first Phase 1 human trial of a vaccine against Bundibugyo ebolavirus on 13 July 2026. The BD-Ebov trial, run by the Oxford Vaccine Group and Pandemic Sciences Institute, will evaluate the safety and immune response of the ChAdOx1 BDBV candidate — built on the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine — in 50 healthy adults aged 18-55. The Serum Institute of India manufactured and stockpiled roughly 620,000 doses within two weeks and supplied 4,000 investigational doses for the study. CEPI is backing the trial, and preparations are underway for additional studies in Uganda through the MRC/Uganda Virus Research Institute and LSHTM Uganda Research Unit.